Cover Image
Market Research Report

Antihypertensive Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Published by Transparency Market Research Product code 926714
Published Content info 213 Pages
Delivery time: 1-2 business days
Price
Back to Top
Antihypertensive Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
Published: January 9, 2020 Content info: 213 Pages
Description

Title:
Antihypertensive Drugs Market (Drug: Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-blockers, Vasodilators, Calcium Channel Blockers, Renin Inhibitors, Alpha-blockers, and Others; Condition: Primary Hypertension and Secondary Hypertension; Medication Type: Monotherapy, Combination Therapy, and Fixed Dose Combinations; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027.

Antihypertensive Drugs Market - Scope of the Report

TMR's report on the global antihypertensive drugs market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period from 2019 to 2027. The report provides the overall market revenue of the antihypertensive drugs market for the period of 2017-2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the antihypertensive drugs market for the forecast period.

The report has been prepared after an extensive research. Primary research involves bulk of research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players' product literature, annual reports, press releases, and relevant documents to understand the antihypertensive drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the antihypertensive drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the antihypertensive drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the antihypertensive drugs market. The next section of the antihypertensive drugs report highlights the USPs, which include regulatory scenario, reimbursement scenario, key mergers & acquisitions, technological advancements, and key industry developments in the antihypertensive drugs market.

The report delves into the competitive landscape of the antihypertensive drugs market. Key players operating in the antihypertensive drugs market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of players in the antihypertensive drugs market profiled in this report.

Key Questions Answered in Antihypertensive Drugs Market Report

What are the major drivers, restraints, and opportunities in the market?

What will be the revenue share projections of key segments in the antihypertensive drugs market during the forecast period?

Which segment is likely to lead the antihypertensive drugs market in terms of revenue by 2027?

How mergers & acquisitions among players are widening the scope for antihypertensive drugs market?

What are the market positions of different companies operating in the global antihypertensive drugs market?

Antihypertensive Drugs Market - Research Objectives and Research Approach

The comprehensive report on the antihypertensive drugs market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides a detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in the purview of research in the antihypertensive drugs market. It is followed by market introduction, market dynamics, and an overview of the antihypertensive drugs market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the antihypertensive drugs market. Furthermore, to understand the Y-o-Y trends of the antihypertensive drugs market, a Y-o-Y analysis with elaborated insights on the same has been provided. The next section of the antihypertensive drugs report highlights the USPs, which include regulatory scenario, reimbursement scenario, key mergers & acquisitions, technological advancements, and key industry developments in the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the antihypertensive drugs market in terms of drug, condition, medication type, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2027 has been provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investments in the antihypertensive drugs market.

Table of Contents
Product Code: TMRGL7718

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Antihypertensive Drugs Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017-2027
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

  • 5.1. Key Industry Developments
  • 5.2. Regulatory Scenario
  • 5.3. Reimbursement Scenario
  • 5.4. Key Mergers & Acquisitions
  • 5.5. Technological Advancements

6. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug

  • 6.1. Introduction & Definition
  • 6.2. Global Antihypertensive Drugs Market Value Forecast, by Drug, 2017-2027
    • 6.2.1. Diuretics
      • 6.2.1.1. Thiazide Diuretics
      • 6.2.1.2. Loop Diuretics
      • 6.2.1.3. Potassium-sparing Diuretics
    • 6.2.2. Angiotensin Converting Enzyme Inhibitors
    • 6.2.3. Angiotensin Receptor Blockers
    • 6.2.4. Beta-blockers
      • 6.2.4.1. Beta-1 Selective
      • 6.2.4.2. Intrinsic Sympathomimetic
    • 6.2.5. Vasodilators
    • 6.2.6. Calcium Channel Blockers
    • 6.2.7. Renin Inhibitors
    • 6.2.8. Alpha-blockers
    • 6.2.9. Others
  • 6.3. Global Antihypertensive Drugs Market Attractiveness, by Drug

7. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition

  • 7.1. Introduction & Definition
  • 7.2. Global Antihypertensive Drugs Market Value Forecast, by Condition, 2017-2027
    • 7.2.1. Primary Hypertension
    • 7.2.2. Secondary Hypertension
  • 7.3. Global Antihypertensive Drugs Market Attractiveness, by Condition

8. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type

  • 8.1. Introduction
  • 8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2027
    • 8.2.1. Monotherapy
    • 8.2.2. Combination Therapy
    • 8.2.3. Fixed Dose Combinations
  • 8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type

9. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 9.2.1. Retail Pharmacies
    • 9.2.2. Hospital Pharmacies
    • 9.2.3. Online Pharmacies
    • 9.2.4. Others
  • 9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel

10. Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Region

  • 10.1. Introduction
  • 10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017-2027
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Global Antihypertensive Drugs Market Attractiveness, by Region

11. North America Antihypertensive Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. North America Antihypertensive Drugs Market Value Forecast, by Drug, 2017-2027
    • 11.2.1. Diuretics
      • 11.2.1.1. Thiazide Diuretics
      • 11.2.1.2. Loop Diuretics
      • 11.2.1.3. Potassium-sparing Diuretics
    • 11.2.2. Angiotensin Converting Enzyme Inhibitors
    • 11.2.3. Angiotensin Receptor Blockers
    • 11.2.4. Beta-blockers
      • 11.2.4.1. Beta-1 Selective
      • 11.2.4.2. Intrinsic Sympathomimetic
    • 11.2.5. Vasodilators
    • 11.2.6. Calcium Channel Blockers
    • 11.2.7. Renin Inhibitors
    • 11.2.8. Alpha-blockers
    • 11.2.9. Others
  • 11.3. North America Antihypertensive Drugs Market Value Forecast, by Condition, 2017-2027
    • 11.3.1. Primary Hypertension
    • 11.3.2. Secondary Hypertension
  • 11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2027
    • 11.4.1. Monotherapy
    • 11.4.2. Combination Therapy
    • 11.4.3. Fixed Dose Combinations
    • 11.4.4. Others
  • 11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 11.5.1. Retail Pharmacies
    • 11.5.2. Hospital Pharmacies
    • 11.5.3. Online Pharmacies
    • 11.5.4. Others
  • 11.6. North America Antihypertensive Drugs Market Value Forecast, by Country, 2017-2027
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. North America Antihypertensive Drugs Market Attractiveness Analysis
    • 11.7.1. By Drug
    • 11.7.2. By Condition
    • 11.7.3. By Medication Type
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Antihypertensive Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Europe Antihypertensive Drugs Market Value Forecast, by Drug, 2017-2027
    • 12.2.1. Diuretics
      • 12.2.1.1. Thiazide Diuretics
      • 12.2.1.2. Loop Diuretics
      • 12.2.1.3. Potassium-sparing Diuretics
    • 12.2.2. Angiotensin Converting Enzyme Inhibitors
    • 12.2.3. Angiotensin Receptor Blockers
    • 12.2.4. Beta-blockers
      • 12.2.4.1. Beta-1 Selective
      • 12.2.4.2. Intrinsic Sympathomimetic
    • 12.2.5. Vasodilators
    • 12.2.6. Calcium Channel Blockers
    • 12.2.7. Renin Inhibitors
    • 12.2.8. Alpha-blockers
    • 12.2.9. Others
  • 12.3. Europe Antihypertensive Drugs Market Value Forecast, by Condition, 2017-2027
    • 12.3.1. Primary Hypertension
    • 12.3.2. Secondary Hypertension
  • 12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2027
    • 12.4.1. Monotherapy
    • 12.4.2. Combination Therapy
    • 12.4.3. Fixed Dose Combinations
    • 12.4.4. Others
  • 12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 12.5.1. Retail Pharmacies
    • 12.5.2. Hospital Pharmacies
    • 12.5.3. Online Pharmacies
    • 12.5.4. Others
  • 12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2027
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis
    • 12.7.1. By Drug
    • 12.7.2. By Condition
    • 12.7.3. By Medication Type
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Drug, 2017-2027
    • 13.2.1. Diuretics
      • 13.2.1.1. Thiazide Diuretics
      • 13.2.1.2. Loop Diuretics
      • 13.2.1.3. Potassium-sparing Diuretics
    • 13.2.2. Angiotensin Converting Enzyme Inhibitors
    • 13.2.3. Angiotensin Receptor Blockers
    • 13.2.4. Beta-blockers
      • 13.2.4.1. Beta-1 Selective
      • 13.2.4.2. Intrinsic Sympathomimetic
    • 13.2.5. Vasodilators
    • 13.2.6. Calcium Channel Blockers
    • 13.2.7. Renin Inhibitors
    • 13.2.8. Alpha-blockers
    • 13.2.9. Others
  • 13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Condition, 2017-2027
    • 13.3.1. Primary Hypertension
    • 13.3.2. Secondary Hypertension
  • 13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2027
    • 13.4.1. Monotherapy
    • 13.4.2. Combination Therapy
    • 13.4.3. Fixed Dose Combinations
    • 13.4.4. Others
  • 13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 13.5.1. Retail Pharmacies
    • 13.5.2. Hospital Pharmacies
    • 13.5.3. Online Pharmacies
    • 13.5.4. Others
  • 13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2027
    • 13.6.1. Japan
    • 13.6.2. China
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis
    • 13.7.1. By Drug
    • 13.7.2. By Condition
    • 13.7.3. By Medication Type
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Antihypertensive Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Drug, 2017-2027
    • 14.2.1. Diuretics
      • 14.2.1.1. Thiazide Diuretics
      • 14.2.1.2. Loop Diuretics
      • 14.2.1.3. Potassium-sparing Diuretics
    • 14.2.2. Angiotensin Converting Enzyme Inhibitors
    • 14.2.3. Angiotensin Receptor Blockers
    • 14.2.4. Beta-blockers
      • 14.2.4.1. Beta-1 Selective
      • 14.2.4.2. Intrinsic Sympathomimetic
    • 14.2.5. Vasodilators
    • 14.2.6. Calcium Channel Blockers
    • 14.2.7. Renin Inhibitors
    • 14.2.8. Alpha-blockers
    • 14.2.9. Others
  • 14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Condition, 2017-2027
    • 14.3.1. Primary Hypertension
    • 14.3.2. Secondary Hypertension
  • 14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2027
    • 14.4.1. Monotherapy
    • 14.4.2. Combination Therapy
    • 14.4.3. Fixed Dose Combinations
    • 14.4.4. Others
  • 14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 14.5.1. Retail Pharmacies
    • 14.5.2. Hospital Pharmacies
    • 14.5.3. Online Pharmacies
    • 14.5.4. Others
  • 14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2027
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Latin America Antihypertensive Drugs Market Attractiveness Analysis
    • 14.7.1. By Drug
    • 14.7.2. By Condition
    • 14.7.3. By Medication Type
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast

  • 15.1. Introduction
  • 15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Drug, 2017-2027
    • 15.2.1. Diuretics
      • 15.2.1.1. Thiazide Diuretics
      • 15.2.1.2. Loop Diuretics
      • 15.2.1.3. Potassium-sparing Diuretics
    • 15.2.2. Angiotensin Converting Enzyme Inhibitors
    • 15.2.3. Angiotensin Receptor Blockers
    • 15.2.4. Beta-blockers
      • 15.2.4.1. Beta-1 Selective
      • 15.2.4.2. Intrinsic Sympathomimetic
    • 15.2.5. Vasodilators
    • 15.2.6. Calcium Channel Blockers
    • 15.2.7. Renin Inhibitors
    • 15.2.8. Alpha-blockers
    • 15.2.9. Others
  • 15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Condition, 2017-2027
    • 15.3.1. Primary Hypertension
    • 15.3.2. Secondary Hypertension
  • 15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2027
    • 15.4.1. Monotherapy
    • 15.4.2. Combination Therapy
    • 15.4.3. Fixed Dose Combinations
    • 15.4.4. Others
  • 15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2027
    • 15.5.1. Retail Pharmacies
    • 15.5.2. Hospital Pharmacies
    • 15.5.3. Online Pharmacies
    • 15.5.4. Others
  • 15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2027
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Israel
    • 15.6.4. Rest of Middle East & Africa
  • 15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis
    • 15.7.1. By Drug
    • 15.7.2. By Condition
    • 15.7.3. By Medication Type
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Global Antihypertensive Drugs Market Share Analysis, by Company (2018)
  • 16.2. Company Profiles
    • 16.2.1. Pfizer Inc.
      • 16.2.1.1. Company Description
      • 16.2.1.2. Business Overview
      • 16.2.1.3. Financial Overview
      • 16.2.1.4. Strategic Overview
      • 16.2.1.5. SWOT Analysis
    • 16.2.2. Sanofi S.A
      • 16.2.2.1. Company Description
      • 16.2.2.2. Business Overview
      • 16.2.2.3. Financial Overview
      • 16.2.2.4. Strategic Overview
      • 16.2.2.5. SWOT Analysis
    • 16.2.3. Novartis AG
      • 16.2.3.1. Company Description
      • 16.2.3.2. Business Overview
      • 16.2.3.3. Financial Overview
      • 16.2.3.4. Strategic Overview
      • 16.2.3.5. SWOT Analysis
    • 16.2.4. Boehringer Ingelheim GmbH
      • 16.2.4.1. Company Description
      • 16.2.4.2. Business Overview
      • 16.2.4.3. Financial Overview
      • 16.2.4.4. Strategic Overview
      • 16.2.4.5. SWOT Analysis
    • 16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)
      • 16.2.5.1. Company Description
      • 16.2.5.2. Business Overview
      • 16.2.5.3. Financial Overview
      • 16.2.5.4. Strategic Overview
      • 16.2.5.5. SWOT Analysis
    • 16.2.6. F. Hoffmann-La Roche Ltd.
      • 16.2.6.1. Company Description
      • 16.2.6.2. Business Overview
      • 16.2.6.3. Financial Overview
      • 16.2.6.4. Strategic Overview
      • 16.2.6.5. SWOT Analysis
    • 16.2.7. Bayer AG
      • 16.2.7.1. Company Description
      • 16.2.7.2. Business Overview
      • 16.2.7.3. Financial Overview
      • 16.2.7.4. Strategic Overview
      • 16.2.7.5. SWOT Analysis
    • 16.2.8. Daiichi Sankyo Company, Limited
      • 16.2.8.1. Company Description
      • 16.2.8.2. Business Overview
      • 16.2.8.3. Financial Overview
      • 16.2.8.4. Strategic Overview
      • 16.2.8.5. SWOT Analysis
    • 16.2.9. Takeda Pharmaceutical Company Limited
      • 16.2.9.1. Company Description
      • 16.2.9.2. Business Overview
      • 16.2.9.3. Financial Overview
      • 16.2.9.4. Strategic Overview
      • 16.2.9.5. SWOT Analysis

List of Tables

  • Table 01: Hospital Inpatient Billing and Payment Reimbursement Scenario
  • Table 02: Physician Billing and Payment for Reimbursement
  • Table 03: Key Mergers and Acquisitions
  • Table 04: Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 05: Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition, 2017-2027
  • Table 06: Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type, 2017-2027
  • Table 07: Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 08: Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • Table 09: North America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • Table 10: North America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 11: North America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition, 2017?2027
  • Table 12: North America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type, 2017?2027
  • Table 13: North America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
  • Table 14: Europe Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 15: Europe Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 16: Europe Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type, 2017?2027
  • Table 17: Europe Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition, 2017?2027
  • Table 18: Europe Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
  • Table 19: Asia Pacific Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 20: Asia Pacific Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 21: Asia Pacific Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition, 2017?2027
  • Table 22: Asia Pacific Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type, 2017?2027
  • Table 23: Asia Pacific Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
  • Table 24: Latin America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 25: Latin America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 26: Latin America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition, 2017?2027
  • Table 27: Latin America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type, 2017?2027
  • Table 28: Latin America Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
  • Table 29: Middle East & Africa Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 30: Middle East & Africa Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Drug, 2017-2027
  • Table 31: Middle East & Africa Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Condition, 2017?2027
  • Table 32: Middle East & Africa Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Medication Type, 2017?2027
  • Table 33: Middle East & Africa Antihypertensive Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027

List of Figures

  • Figure 01: Global Antihypertensive Drugs Market Value (US$ Mn) Forecast and Distribution (%), by Region, 2019 and 2027
  • Figure 02: Antihypertensive Drugs Market - Key Industry Developments
  • Figure 03: Market Drivers
  • Figure 04: Market Restraints
  • Figure 05: Key Opportunities
  • Figure 06: Global Antihypertensive Drugs Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 07: Global Antihypertensive Drugs Market Value Share (%), by Drug (2018)
  • Figure 08: Global Antihypertensive Drugs Market Value Share (%), by Condition (2018)
  • Figure 09: Global Antihypertensive Drugs Market Value Share (%), by Medication Type (2018)
  • Figure 10: Global Antihypertensive Drugs Market Value Share (%), by Distribution Channel (2018)
  • Figure 11: Europe Regulatory Approval Process
  • Figure 12: Technological Advancements
  • Figure 13: Global Antihypertensive Drugs Market Value Share (%), by Drug, 2018 and 2027
  • Figure 14: Global Antihypertensive Drugs Market Attractiveness, by Drug, 2019-2027
  • Figure 15: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diuretics, 2017-2027
  • Figure 16: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Angiotensin Converting Enzyme Inhibitors, 2017-2027
  • Figure 17: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vasodilators, 2017-2027
  • Figure 18: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Calcium Channel Blockers, 2017-2027
  • Figure 19: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 20: Global Antihypertensive Drugs Market Value Share (%), by Condition, 2018 and 2027
  • Figure 21: Global Antihypertensive Drugs Market Attractiveness, by Condition, 2019-2027
  • Figure 22: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Secondary Hypertension, 2017-2027
  • Figure 23: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Primary Hypertension, 2017-2027
  • Figure 24: Global Antihypertensive Drugs Market Value Share (%), by Medication Type, 2018 and 2027
  • Figure 25: Global Antihypertensive Drugs Market Attractiveness, by Medication Type, 2019-2027
  • Figure 26: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Monotherapy, 2017-2027
  • Figure 27: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fixed Dose Combinations, 2017-2027
  • Figure 28: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 29: Global Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2018 and 2027
  • Figure 30: Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 31: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2027
  • Figure 32: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 33: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017-2027
  • Figure 34: Global Antihypertensive Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2027
  • Figure 35: Global Antihypertensive Drugs Market: Regional Outlook
  • Figure 36: Global Antihypertensive Drugs Market Value Share (%), by Region, 2018 and 2027
  • Figure 37: Global Antihypertensive Drugs Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 38: North America Antihypertensive Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 39: North America Antihypertensive Drugs Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 40: North America Antihypertensive Drugs Market Attractiveness Analysis, by Country, 2019-2027
  • Figure 41: North America Antihypertensive Drugs Market Value Share (%), by Drug, 2018 and 2027
  • Figure 42: North America Antihypertensive Drugs Market Attractiveness, by Drug, 2019-2027
  • Figure 43: North America Antihypertensive Drugs Market Value Share (%), by Condition, 2018 and 2027
  • Figure 44: North America Antihypertensive Drugs Market Attractiveness, by Condition, 2019-2027
  • Figure 45: North America Antihypertensive Drugs Market Value Share (%), by Medication Type, 2018 and 2027
  • Figure 46: North America Antihypertensive Drugs Market Attractiveness, by Medication Type, 2019-2027
  • Figure 47: North America Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2018 and 2027
  • Figure 48: North America Antihypertensive Drugs Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 49: Europe Antihypertensive Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 50: Europe Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 51: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 52: Europe Antihypertensive Drugs Market Value Share (%), by Drug, 2018 and 2027
  • Figure 53: Europe Antihypertensive Drugs Market Attractiveness, by Drug, 2019-2027
  • Figure 54: Europe Antihypertensive Drugs Market Value Share (%), by Medication Type, 2018 and 2027
  • Figure 55: Europe Antihypertensive Drugs Market Attractiveness, by Medication Type, 2019-2027
  • Figure 56: Europe Antihypertensive Drugs Market Value Share (%), by Condition, 2018 and 2027
  • Figure 57: Europe Antihypertensive Drugs Market Attractiveness, by Condition, 2019-2027
  • Figure 58: Europe Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2018 and 2027
  • Figure 59: Europe Antihypertensive Drugs Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 60: Asia Pacific Antihypertensive Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 61: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 62: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 63: Asia Pacific Antihypertensive Drugs Market Value Share (%), by Drug, 2018 and 2027
  • Figure 64: Asia Pacific Antihypertensive Drugs Market Attractiveness, by Drug, 2019-2027
  • Figure 65: Asia Pacific Antihypertensive Drugs Market Value Share (%), by Condition, 2018 and 2027
  • Figure 66: Asia Pacific Antihypertensive Drugs Market Attractiveness, by Condition, 2019-2027
  • Figure 67: Asia Pacific Antihypertensive Drugs Market Value Share (%), by Medication Type, 2018 and 2027
  • Figure 68: Asia Pacific Antihypertensive Drugs Market Attractiveness, by Medication Type, 2019-2027
  • Figure 69: Asia Pacific Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2018 and 2027
  • Figure 70: Asia Pacific Antihypertensive Drugs Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 71: Latin America Antihypertensive Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 72: Latin America Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 73: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 74: Latin America Antihypertensive Drugs Market Value Share (%), by Drug, 2018 and 2027
  • Figure 75: Latin America Antihypertensive Drugs Market Attractiveness, by Drug, 2019-2027
  • Figure 76: Latin America Antihypertensive Drugs Market Value Share (%), by Condition, 2018 and 2027
  • Figure 77: Latin America Antihypertensive Drugs Market Attractiveness, by Condition, 2019-2027
  • Figure 78: Latin America Antihypertensive Drugs Market Value Share (%), by Medication Type, 2018 and 2027
  • Figure 79: Latin America Antihypertensive Drugs Market Attractiveness, by Medication Type, 2019-2027
  • Figure 80: Latin America Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2018 and 2027
  • Figure 81: Latin America Antihypertensive Drugs Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 82: Middle East & Africa Antihypertensive Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 83: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 84: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 85: Middle East & Africa Antihypertensive Drugs Market Value Share (%), by Drug, 2018 and 2027
  • Figure 86: Middle East & Africa Antihypertensive Drugs Market Attractiveness, by Drug, 2019-2027
  • Figure 87: Middle East & Africa Antihypertensive Drugs Market Value Share (%), by Condition, 2018 and 2027
  • Figure 88: Middle East & Africa Antihypertensive Drugs Market Attractiveness, by Condition, 2019-2027
  • Figure 89: Middle East & Africa Antihypertensive Drugs Market Value Share (%), by Medication Type, 2018 and 2027
  • Figure 90: Middle East & Africa Antihypertensive Drugs Market Attractiveness, by Medication Type, 2019-2027
  • Figure 91: Middle East & Africa Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2018 and 2027
  • Figure 92: Middle East & Africa Antihypertensive Drugs Market Attractiveness, by Distribution Channel, 2019-2027
  • Figure 93: Global Antihypertensive Drugs Market Share Analysis, by Company (2018)
Back to Top